Journal article
Repetitive high-dose therapy with ifosfamide, thiotepa and paclitaxel (ITP) with blood cell (BC) support for metastatic breast cancer (MBC): Results of a phase I study
HM Prince, MJ Millward, D Rischin, D Blakey, M Wolf, H Januscewicz, G Toner, I Bertoncello, G Richardson, P Briggs, J Scarlett, P Gates, B Dale
EXPERIMENTAL HEMATOLOGY | CARDEN JENNINGS PUBL CO LTD | Published : 1998
Abstract
Between August 1996 and Jan 1998, 23 patients (pts) with MBC (n=20) or locally advanced disease (n=3) were enrolled in this Phase I study (mean age = 44yrs, range: 32-58). Pts had received a median of 2 prior regimens (1-5) of conventional-dose chemotherapy prior to the first cycle of high-dose therapy. 12 pts had chemotherapy-refractory disease. BCs were mobilised with augmenteddose ifosfamide (6g/m2) and either doxomhicin (50mg/m2) or paclitaxel (175mg/m2) followed by daily G-CSF (10ug/kg). BCs were collected over 2-5 consecutive days and equally divided into three aliquots and cryopreserved. Five cohorts were treated with a planned 3 cycles (q24d) of ifosfamide/mesna (IF:24 hr infusion; d..
View full abstract